A TPS system, or transcranial pulse stimulation, is a noninvasive brain stimulation technology that uses focused ultrasound shockwaves to reach and activate targeted areas of the brain. It is one of the newest tools in the field of neurostimulation, primarily being studied as a treatment for Alzheimer’s disease and other neurological conditions. Unlike older brain stimulation methods, TPS can reach deeper brain structures with greater precision.
How TPS Works
TPS delivers repetitive, ultrashort shockwave pulses in the ultrasound frequency range through the skull and into specific brain regions. A handheld device is placed against the scalp and guided by real-time brain imaging, allowing clinicians to aim the pulses at precise targets.
The underlying process is called mechanotransduction. In simple terms, brain cells sense the physical pressure of each shockwave pulse and convert that mechanical force into chemical signals. Those signals can influence basic cell behaviors like growth, repair, and communication between neurons. This is fundamentally different from how older stimulation methods work. Rather than using electricity or magnetism, TPS uses physical vibration to nudge cells into action.
How TPS Differs From Magnetic Stimulation
The better-known brain stimulation method is transcranial magnetic stimulation (TMS), which uses an electromagnetic coil on the scalp to generate a magnetic field that activates nerve cells. TMS has been widely used for treatment-resistant depression for years. However, standard TMS primarily reaches the outer layers of the brain. Even “deep TMS,” which uses a different coil design, stimulates broader but still relatively limited areas.
TPS has a potential advantage in penetration depth. Because it uses focused ultrasound pulses rather than magnetic fields, TPS can reach deeper and more targeted brain structures. This matters for conditions like Alzheimer’s disease, where damage often occurs in regions buried well beneath the brain’s surface, such as the memory-related areas in the temporal lobes and the precuneus (a region involved in memory retrieval and self-awareness).
What a Treatment Session Looks Like
A typical TPS session lasts about 40 minutes. During each session, around 6,000 ultrasound pulses are delivered at a rate of 4 pulses per second. The pulses are directed at multiple brain regions, including areas in the frontal, parietal, and temporal lobes on both sides of the brain.
The standard protocol starts with six sessions spread over two weeks, scheduled every other day. After that initial block, patients receive a single booster session once a month. In research settings, these monthly boosters have continued for up to twelve months. The treatment is done while the patient is awake and seated, with no anesthesia required.
Evidence for Alzheimer’s Disease
Most of the clinical research on TPS has focused on Alzheimer’s disease. Several studies have found that patients show measurable cognitive improvement after completing a course of TPS sessions. In standardized memory and language tests (known as the CERAD battery), patients demonstrated significant gains in memory and verbal ability after treatment, and those improvements remained stable for at least three months.
One study found a 15.76% improvement in a comprehensive Alzheimer’s assessment score and an 8.65% improvement in the cognitive portion of that same test. Mood-related symptoms also improved: patients showed reduced scores on depression scales. The results were not uniform across every cognitive measure, though. Some studies found no significant changes on certain screening tests like the MMSE, while others did. Figural ability, which involves processing visual and spatial information, was one area that did not consistently improve.
These are modest but meaningful gains for a disease that currently has very few effective treatments. The fact that benefits persisted for months after the initial treatment block suggests TPS may trigger lasting changes in brain connectivity rather than just temporary activation.
Research Beyond Alzheimer’s
Researchers are beginning to explore TPS for other neurological and psychiatric conditions. Early investigations have looked at Parkinson’s disease, depression, and disorders of consciousness (conditions where patients have severely reduced awareness, such as after a brain injury). In Parkinson’s disease specifically, a first retrospective analysis has been published, though the field is still in early stages.
There is already evidence from controlled studies using EEG and brain imaging that TPS produces measurable neurophysiological changes: it modifies how the brain processes sensory information and promotes long-term neuroplastic changes, essentially helping the brain rewire itself. These effects have been documented independently in both Alzheimer’s and depression research, which supports the idea that TPS may have broad applications across multiple brain conditions.
Regulatory Status and Availability
TPS devices currently hold CE certification in Europe, meaning they have met European safety and quality standards for medical devices (under ISO 9001 and ISO 13485). This allows the technology to be used clinically in European countries.
In the United States, TPS is not yet cleared by the FDA. Clinical trials are underway to gather the data needed for potential approval, but for now, American patients can only access TPS through research studies. If you’re in the U.S. and interested, searching ClinicalTrials.gov for transcranial pulse stimulation will show active enrollment opportunities.
What Sets TPS Apart
The combination of features that makes TPS distinctive is its ability to reach deep brain structures noninvasively, its use of real-time imaging for precise targeting, and the fact that it relies on mechanical rather than electromagnetic energy. For patients, the practical appeal is straightforward: sessions are relatively short, the treatment doesn’t require surgery or sedation, and the initial course is completed in just two weeks. Monthly maintenance sessions add minimal ongoing time commitment compared to treatments that require daily or weekly visits.
TPS is still a young technology, and the published studies involve relatively small patient groups. But the consistency of cognitive improvements across multiple independent research teams, combined with evidence of lasting brain changes on imaging, has generated significant interest in the neurology community. For people living with Alzheimer’s or other neurodegenerative conditions, it represents a genuinely new approach rather than a variation on existing methods.